INTRODUCTION: The role of stereotactic body radiation therapy (SBRT) in @entity1 with metastatic @entity2 harboring @entity470 ( @entity470 ) mutations is not defined. We evaluated the pattern of failure in @entity1 receiving @entity4149 kinase inhibitor (TKI) therapy to identify candidates for consolidation SBRT. METHODS: Computed tomography scans were reviewed in a cohort of @entity470 -mutant @entity1 enrolled on prospective TKI trials. Initial progression in sites of original disease (primary/metastatic) or new sites was classified as @entity177 ( @entity177 ) or distant site failure (DF), respectively. Simultaneous @entity177 /DF was labeled @entity19224 . Disease characteristics were analyzed for associations with patterns of failure using actuarial competing risks methodology. RESULTS: Complete serial imaging was available in 49 @entity1 with measurable disease. Median time to any progression was 8.3 months. The majority failed initially in original disease sites with @entity177 , @entity19224 , and DF frequencies being 47.0%, 32.6%, and 20.4%, respectively. Primary @entity5 size was the most significant predictor of @entity177 in univariate and multivariate analysis (p = 0.004). Median time to progression was 3 months shorter in @entity1 with @entity177 compared with DF. Ten @entity1 (20%) were retroactively classified as consolidation SBRT candidates based on the extent of disease at time of best response to TKI therapy, and in seven of these, initial progression occurred in original @entity5 sites. CONCLUSION: Initial progression of TKI-treated @entity5 occurred @entity66 sites. Consolidation SBRT was judged feasible in a subset of @entity1 following maximum TKI response and may have prevented oligoprogression in most of these. In addition, we hypothesize that consolidation SBRT for @entity66 could delay subsequent metastatic reseeding.

Pattern of Failure Analysis in Metastatic XXXX -Mutant Lung Cancer Treated with @entity4149 Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'predominantly in original disease'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity177 :: ('MESH:D051437', 'Disease') :: ['OF', 'original site failure'] @entity19224 :: ('4956', 'Gene') :: ['ODF'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity470 :: (1956,Gene) :: ['EGFR']
